Global Hemostats Market Share Grows Steadily at a CAGR of 6.57%

Introduction

The global hemostats market is experiencing significant growth due to a combination of critical factors. One major contributor is the increasing incidence of bleeding disorders like hemophilia and von Willebrand disease, which demand effective solutions for bleeding control. Moreover, the rise in trauma cases and road accidents globally has heightened the need for fast-acting and dependable hemostatic agents in emergency medical settings. The surging focus on enhancing patient safety and reducing surgical complications is also driving the adoption of hemostats to control bleeding during and after surgeries.

In addition, regulatory mandates and hospital protocols emphasizing efficient blood management are promoting the shift toward topical hemostats over conventional techniques. The healthcare sector’s push for shorter hospital stays and better surgical outcomes is further boosting the demand for advanced hemostatic products. Together, these dynamics are propelling the widespread use of hemostats in hospitals, ambulatory surgical centers, and trauma care units.

Market Dynamics

Rising surgical procedures globally drive the global market

One of the key aspects augmenting the growth of the global market is the increasing volume of surgical procedures worldwide. This rise is largely attributed to the growing incidence of chronic illnesses like cardiovascular diseases, cancer, and orthopedic conditions.

• As reported by the World Health Organization (WHO), more than 310 million major surgical operations are carried out globally each year. Additionally, the expanding elderly population, who are more likely to require surgical care, further fuels this demand. For example, the American Heart Association noted that over 1.2 million coronary artery bypass grafting (CABG) surgeries were conducted in the United States in 2023 alone.

The rising number of surgeries has led to greater demand for effective bleeding management solutions, thereby propelling the market for hemostatic agents. Furthermore, the expansion of surgical infrastructure in emerging economies is accelerating the need for reliable and rapid-acting hemostatic products in various healthcare settings.

Expansion in emerging markets creates tremendous opportunities

Rising healthcare spending and infrastructural advancements in emerging economies are creating significant growth prospects for the global market. As countries in the developing world continue to upgrade their hospital infrastructure and enhance surgical capabilities, the need for surgical consumables, such as hemostatic agents, is on the rise.

• For example, the UAE Cabinet has earmarked AED 5.745 billion (around 8% of the federal budget) for healthcare and community health initiatives in its 2025 fiscal plan. Likewise, India’s Union Budget 2023 allocated more than ₹89,000 crore (approximately USD 11 billion) to the healthcare sector, with a strong emphasis on expanding tertiary care services.

These financial commitments are driving the expansion of both public and private surgical and trauma centers, which in turn boosts the demand for effective bleeding control products. To meet the needs of these price-sensitive, high-volume regions, including Asia, the Middle East, and Latin America, global manufacturers are increasingly localizing production and introducing affordable hemostatic solutions.

Regional Insights

North America dominates the global hemostats market due to its advanced healthcare infrastructure, high volume of surgical procedures, and strong presence of leading manufacturers like Baxter International, Johnson & Johnson, and Pfizer. The U.S. accounts for the largest share, driven by increasing cardiovascular and orthopedic surgeries. For instance, the American Heart Association reported over 1.3 million open-heart surgeries in 2023, contributing significantly to the demand for hemostatic agents.

Furthermore, the FDA's streamlined approval processes have accelerated the launch of innovative products, such as Ethicon’s SURGIFLO® Hemostatic Matrix. Canada is also witnessing steady growth due to increased surgical admissions and government investment in operating room safety and efficiency. Moreover, initiatives promoting blood loss reduction during procedures, particularly in ambulatory surgical centers, are creating a supportive environment for advanced topical hemostats and sealants across the region.

Key Highlights

• The global hemostats market size was valued at USD 2.98 billion in 2024 and is projected to grow from USD 3.18 billion in 2025 to reach USD 5.28 billion by 2033, growing at a CAGR of 6.57% during the forecast period (2025–2033).
• By type, the global hemostats market is segmented into thrombin-based hemostats, oxidized regenerated cellulose-based hemostats, combination hemostats, and others. The oxidized regenerated cellulose-based hemostats segment dominated the market.

• By formulation, the market is categorized into matrix & gel hemostats, sheet & pad hemostats, sponge hemostats, powder hemostats, and others. The matrix & gel hemostats segment contributed the largest market share.

• By application, the market is divided into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, reconstructive surgery, gynecological surgery, and others. The orthopedic surgery segment held a dominant market share.

• By end-user, the market is segmented into hospitals & clinics, ambulatory surgical centers, casualty care centers, and others. The hospitals & clinics segment dominated the market.
• North America is the highest shareholder in the global market.

Competitive Players

Johnson & Johnson (Ethicon), Baxter International Inc., B. Braun Melsungen AG, Medtronic plc, Pfizer Inc., Integra LifeSciences Corporation, Teleflex Incorporated, CSL Behring, BD (Becton, Dickinson and Company), Z-Medica LLC (a Stryker company), Hemostasis LLC, Arch Therapeutics Inc., and others.

Recent Developments

• In June 2025- Johnson & Johnson MedTech launched the ETHICON™ 4000 Stapler, featuring proprietary 3D Staple Technology and enhanced Gripping Surface Technology (GST). This advanced stapler is designed to manage tissue complexities and deliver exceptional staple line integrity, minimizing risks of surgical leaks and bleeding complications across specialties. The ETHICON 4000 Stapler is approved for use in open and laparoscopic surgeries and is planned for future use exclusively on the OTTAVA™ Robotic Surgical System.

Segmentation

1. By Type
   1. Thrombin Based Hemostats
   2. Oxidized Regenerated Cellulose Based Hemostats
   3. Combination Hemostats
   4. Others
2. By Formulation
   1. Matrix & Gel Hemostats
   2. Sheet & Pad Hemostats
   3. Sponge Hemostats
   4. Powder Hemostats
   5. Others
3. By Application
   1. Orthopedic Surgery
   2. General Surgery
   3. Neurological Surgery
   4. Cardiovascular Surgery
   5. Reconstructive Surgery
   6. Gynecological Surgery
   7. Others
4. By End-user
   1. Hospitals & Clinics
   2. Ambulatory Surgical Centers
   3. Casualty Care Centers
   4. Others
5. By Regions
   1. North America
   2. Europe
   3. Asia-Pacific
   4. Latin America
   5. The Middle East and Africa